Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
349 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Schizophrenia - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline Review, H2 2016, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape. Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 10, 13, 30, 1, 53, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 8 and 2 molecules, respectively.Schizophrenia. Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 Introduction 6 Schizophrenia Overview 7 Therapeutics Development 8 Schizophrenia - Therapeutics under Development by Companies 10 Schizophrenia - Therapeutics under Investigation by Universities/Institutes 15 Schizophrenia - Pipeline Products Glance 16 Schizophrenia - Products under Development by Companies 20 Schizophrenia - Products under Investigation by Universities/Institutes 28 Schizophrenia - Companies Involved in Therapeutics Development 29 Schizophrenia - Therapeutics Assessment 102 Drug Profiles 119 Schizophrenia - Dormant Projects 302 Schizophrenia - Discontinued Products 316 Schizophrenia - Product Development Milestones 320 Appendix 333
List of Tables Number of Products under Development for Schizophrenia, H2 2016 23 Number of Products under Development for Schizophrenia - Comparative Analysis, H2 2016 24 Number of Products under Development by Companies, H2 2016 25 Number of Products under Development by Companies, H2 2016 (Contd..1) 26 Number of Products under Development by Companies, H2 2016 (Contd..2) 27 Number of Products under Development by Companies, H2 2016 (Contd..3) 28 Number of Products under Development by Companies, H2 2016 (Contd..4) 29 Number of Products under Investigation by Universities/Institutes, H2 2016 30 Comparative Analysis by Late Stage Development, H2 2016 31 Comparative Analysis by Clinical Stage Development, H2 2016 32 Comparative Analysis by Early Stage Development, H2 2016 33 Comparative Analysis by Unknown Stage Development, H2 2016 34 Products under Development by Companies, H2 2016 35 Products under Development by Companies, H2 2016 (Contd..1) 36 Products under Development by Companies, H2 2016 (Contd..2) 37 Products under Development by Companies, H2 2016 (Contd..3) 38 Products under Development by Companies, H2 2016 (Contd..4) 39 Products under Development by Companies, H2 2016 (Contd..5) 40 Products under Development by Companies, H2 2016 (Contd..6) 41 Products under Development by Companies, H2 2016 (Contd..7) 42 Products under Investigation by Universities/Institutes, H2 2016 43 Schizophrenia - Pipeline by Adamed Sp. z o.o., H2 2016 44 Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc., H2 2016 45 Schizophrenia - Pipeline by Aestus Therapeutics, Inc., H2 2016 46 Schizophrenia - Pipeline by AgeneBio Inc., H2 2016 47 Schizophrenia - Pipeline by Alkermes Plc, H2 2016 48 Schizophrenia - Pipeline by Angita B.V., H2 2016 49 Schizophrenia - Pipeline by Astellas Pharma Inc., H2 2016 50 Schizophrenia - Pipeline by Athersys, Inc., H2 2016 51 Schizophrenia - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016 52 Schizophrenia - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016 53 Schizophrenia - Pipeline by BCWorld Pharm Co. Ltd., H2 2016 54 Schizophrenia - Pipeline by BioCrea GmbH, H2 2016 55 Schizophrenia - Pipeline by BioHealthonomics Inc, H2 2016 56 Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H2 2016 57 Schizophrenia - Pipeline by Braeburn Pharmaceuticals, Inc., H2 2016 58 Schizophrenia - Pipeline by Bristol-Myers Squibb Company, H2 2016 59 Schizophrenia - Pipeline by Critical Pharmaceuticals Limited, H2 2016 60 Schizophrenia - Pipeline by Curemark, LLC, H2 2016 61 Schizophrenia - Pipeline by Delpor, Inc., H2 2016 62 Schizophrenia - Pipeline by Denovo Biopharma, LLC, H2 2016 63 Schizophrenia - Pipeline by Echo Pharmaceuticals B.V., H2 2016 64 Schizophrenia - Pipeline by Egis Gyogyszergyar Nyrt, H2 2016 65 Schizophrenia - Pipeline by Evotec AG, H2 2016 66 Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 67 Schizophrenia - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016 68 Schizophrenia - Pipeline by Galenea Corp., H2 2016 69 Schizophrenia - Pipeline by GeNeuro SA, H2 2016 70 Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016 71 Schizophrenia - Pipeline by GP Pharm, S.A., H2 2016 72 Schizophrenia - Pipeline by GW Pharmaceuticals Plc, H2 2016 73 Schizophrenia - Pipeline by H. Lundbeck A/S, H2 2016 74 Schizophrenia - Pipeline by Heptares Therapeutics Limited, H2 2016 75 Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 76 Schizophrenia - Pipeline by Indivior Plc, H2 2016 77 Schizophrenia - Pipeline by INSYS Therapeutics, Inc., H2 2016 78 Schizophrenia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 79 Schizophrenia - Pipeline by IntelGenx Corp., H2 2016 80 Schizophrenia - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 81 Schizophrenia - Pipeline by Jiangsu Nhwa Pharmaceutical Corporation Ltd., H2 2016 82 Schizophrenia - Pipeline by Johnson & Johnson, H2 2016 83 Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc., H2 2016 84 Schizophrenia - Pipeline by KemPharm, Inc., H2 2016 85 Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2016 86 Schizophrenia - Pipeline by Lead Discovery Center GmbH, H2 2016 87 Schizophrenia - Pipeline by Lohocla Research Corporation, H2 2016 88 Schizophrenia - Pipeline by Luye Pharma Group Ltd., H2 2016 89 Schizophrenia - Pipeline by Mapi Pharma Ltd., H2 2016 90 Schizophrenia - Pipeline by Merck & Co., Inc., H2 2016 91 Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 92 Schizophrenia - Pipeline by Neurocrine Biosciences, Inc., H2 2016 93 Schizophrenia - Pipeline by NeurOp, Inc, H2 2016 94 Schizophrenia - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016 95 Schizophrenia - Pipeline by Omeros Corporation, H2 2016 96 Schizophrenia - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 97 Schizophrenia - Pipeline by Peptron, Inc., H2 2016 98 Schizophrenia - Pipeline by Pfizer Inc., H2 2016 99 Schizophrenia - Pipeline by Promentis Pharmaceuticals, Inc., H2 2016 100 Schizophrenia - Pipeline by Ra Pharmaceuticals, Inc., H2 2016 101 Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 102 Schizophrenia - Pipeline by Richter Gedeon Nyrt., H2 2016 103 Schizophrenia - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 104 Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 105 Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 106 Schizophrenia - Pipeline by Suven Life Sciences Ltd., H2 2016 107 Schizophrenia - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 108 Schizophrenia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 109 Schizophrenia - Pipeline by Tetra Discovery Partners LLC, H2 2016 110 Schizophrenia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 111 Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc., H2 2016 112 Schizophrenia - Pipeline by Vitality Biopharma Inc, H2 2016 113 Schizophrenia - Pipeline by VLP Therapeutics, LLC, H2 2016 114 Schizophrenia - Pipeline by Zogenix, Inc., H2 2016 115 Schizophrenia - Pipeline by Zysis Limited, H2 2016 116 Assessment by Monotherapy Products, H2 2016 117 Assessment by Combination Products, H2 2016 118 Number of Products by Stage and Target, H2 2016 120 Number of Products by Stage and Mechanism of Action, H2 2016 125 Number of Products by Stage and Route of Administration, H2 2016 131 Number of Products by Stage and Molecule Type, H2 2016 133 Schizophrenia - Dormant Projects, H2 2016 317 Schizophrenia - Dormant Projects (Contd..1), H2 2016 318 Schizophrenia - Dormant Projects (Contd..2), H2 2016 319 Schizophrenia - Dormant Projects (Contd..3), H2 2016 320 Schizophrenia - Dormant Projects (Contd..4), H2 2016 321 Schizophrenia - Dormant Projects (Contd..5), H2 2016 322 Schizophrenia - Dormant Projects (Contd..6), H2 2016 323 Schizophrenia - Dormant Projects (Contd..7), H2 2016 324 Schizophrenia - Dormant Projects (Contd..8), H2 2016 325 Schizophrenia - Dormant Projects (Contd..9), H2 2016 326 Schizophrenia - Dormant Projects (Contd..10), H2 2016 327 Schizophrenia - Dormant Projects (Contd..11), H2 2016 328 Schizophrenia - Dormant Projects (Contd..12), H2 2016 329 Schizophrenia - Dormant Projects (Contd..13), H2 2016 330 Schizophrenia - Discontinued Products, H2 2016 331 Schizophrenia - Discontinued Products (Contd..1), H2 2016 332 Schizophrenia - Discontinued Products (Contd..2), H2 2016 333 Schizophrenia - Discontinued Products (Contd..3), H2 2016 334
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
